Acetoxyestrone is a synthetic estrogen that is a derivative of estrone. It has been studied as a potential treatment for breast cancer, as it has been shown to inhibit the growth of breast cancer cells in vitro and in vivo. Acetoxyestrone is also being investigated as a potential treatment for other conditions, such as osteoporosis and Alzheimer's disease. It is synthesized by the acetylation of estrone, which is a naturally occurring steroid hormone produced by the ovaries. The mechanism of action of acetoxyestrone is thought to be related to its ability to bind to estrogen receptors, which are found in a variety of tissues, including the breast, uterus, and brain. Acetoxyestrone has also been shown to have anti-inflammatory and antioxidant effects. The compound is studied because of its potential as a therapeutic agent for a variety of conditions. Studies continue to be conducted to further evaluate its efficacy and safety. '
puboestrene: from the bark of Holarrhena pubescens; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 92846 |
| CHEMBL ID | 1627997 |
| SCHEMBL ID | 603954 |
| MeSH ID | M0063864 |
| Synonym |
|---|
| estra-1,3,5(10)-trien-17-one, 3-(acetyloxy)- |
| estrone acetate |
| 901-93-9 |
| 1,3,5[10]-estratrien-3-ol-17-one acetate |
| 3-acetoxyestrone |
| hogival |
| [(8r,9s,13s,14s)-13-methyl-17-oxo-7,8,9,11,12,14,15,16-octahydro-6h-cyclopenta[a]phenanthren-3-yl] acetate |
| CHEMBL1627997 , |
| acetoxyestrone |
| unii-4l6usg266b |
| 4l6usg266b , |
| bdbm50370422 |
| SS-4431 |
| 3-o-acetylestrone |
| 3-acetylestrone |
| oestrone-3-acetate |
| estrone acetate [who-dd] |
| estrone acetate [mi] |
| estrone 3-acetate |
| puboestrene |
| acetylestrone |
| SCHEMBL603954 |
| 17-oxo-1,3,5(10)-estratrien-3-yl acetate |
| AKOS024374937 |
| 3-acetoxyestrone r |
| 3-hydroxyestra-1,3,5(10)-17-one acetate |
| 17-oxoestra-1(10),2,4-trien-3-yl acetate # |
| 3beta-acetoxyestra-1,3,5(10)-trien-17-one |
| 3-acetoxy-17-oxo-estra-1,3,5(10)-triene |
| (8r,9s,13s,14s)-13-methyl-17-oxo-7,8,9,11,12,13,14,15,16,17-decahydro-6h-cyclopenta[a]phenanthren-3-yl acetate |
| estroneacetate |
| Q27259970 |
| DTXSID801009160 |
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Steryl-sulfatase | Homo sapiens (human) | IC50 (µMol) | 50.0000 | 0.0001 | 0.4071 | 7.6000 | AID240903 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| steroid catabolic process | Steryl-sulfatase | Homo sapiens (human) |
| female pregnancy | Steryl-sulfatase | Homo sapiens (human) |
| epidermis development | Steryl-sulfatase | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| steryl-sulfatase activity | Steryl-sulfatase | Homo sapiens (human) |
| sulfuric ester hydrolase activity | Steryl-sulfatase | Homo sapiens (human) |
| metal ion binding | Steryl-sulfatase | Homo sapiens (human) |
| arylsulfatase activity | Steryl-sulfatase | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| lysosome | Steryl-sulfatase | Homo sapiens (human) |
| endosome | Steryl-sulfatase | Homo sapiens (human) |
| endoplasmic reticulum | Steryl-sulfatase | Homo sapiens (human) |
| endoplasmic reticulum lumen | Steryl-sulfatase | Homo sapiens (human) |
| endoplasmic reticulum membrane | Steryl-sulfatase | Homo sapiens (human) |
| Golgi apparatus | Steryl-sulfatase | Homo sapiens (human) |
| plasma membrane | Steryl-sulfatase | Homo sapiens (human) |
| membrane | Steryl-sulfatase | Homo sapiens (human) |
| intracellular membrane-bounded organelle | Steryl-sulfatase | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID240903 | Inhibition of purified human steroid sulfatase | 2004 | Bioorganic & medicinal chemistry letters, Oct-04, Volume: 14, Issue:19 | Estrone formate: a novel type of irreversible inhibitor of human steroid sulfatase. |
| AID1159550 | Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening | 2015 | Nature cell biology, Nov, Volume: 17, Issue:11 | 6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (16.67) | 18.2507 |
| 2000's | 3 (50.00) | 29.6817 |
| 2010's | 2 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.56) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 1 (16.67%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (83.33%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||